527 related articles for article (PubMed ID: 25518352)
1. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
5. Galeterone activity in castration-resistant prostate cancer.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
[No Abstract] [Full Text] [Related]
6. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
7. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
8. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
11. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
Aragon-Ching JB
Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
[No Abstract] [Full Text] [Related]
12. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
Maeda H; Saito A
Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
[TBL] [Abstract][Full Text] [Related]
13. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor antagonists in castration-resistant prostate cancer.
Rathkopf D; Scher HI
Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
[TBL] [Abstract][Full Text] [Related]
15. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
17. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
18. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
19. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Sharp A; Welti J; Blagg J; de Bono JS
Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]